Company Filing History:
Years Active: 2020
Title: Carl Andrew Sterritt: Innovator in Iron Deficiency Treatment
Introduction
Carl Andrew Sterritt is a notable inventor based in Gateshead Quays, GB. He has made significant contributions to the field of medicine, particularly in the treatment of iron deficiency. His innovative approach has led to the development of a specific dosage regimen that addresses the needs of patients suffering from this condition.
Latest Patents
Sterritt holds a patent for a dosage regimen of ferric maltol, specifically known as ST10. This invention relates to the treatment of patients suffering from iron deficiency, with or without anemia. The patent outlines a regimen where the dose of ST10 is administered between 40 mg and 90 mg twice daily. This targeted approach aims to improve patient outcomes and enhance the effectiveness of iron supplementation.
Career Highlights
Throughout his career, Sterritt has worked with various companies, including Shield Tx (UK) Limited and Shield Tx Ltd. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovations and contribute to advancements in medical treatments.
Collaborations
Some of Sterritt's notable coworkers include Nicholas Mallard and Julian David Howell. Their collaboration has likely played a role in the development and success of his innovative projects.
Conclusion
Carl Andrew Sterritt's contributions to the field of iron deficiency treatment through his patent on ferric maltol demonstrate his commitment to improving patient care. His work continues to influence the medical community and offers hope for those affected by iron deficiency.